Self-limited cancer progression with increasing tumor mutations
-
-
REFERENCES
[1] Zheng, M. (2022). Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better. J. Immunother. Cancer 10: e003087. DOI: 10.1136/jitc-2021-003087. [2] FDA. (2020). FDA approves pembrolizumab for adults and children with TMB-H solid tumors. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors. [3] Hsiehchen, D., Espinoza, M., Valero, C., et al. (2021). Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups. J. Immunother. Cancer 9: e003683. DOI: 10.1136/jitc-2021-003683. [4] Shao, C., Li, G., Huang, L., et al. (2020). Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors. JAMA Netw. Open 3: e2025109. DOI: 10.1001/jamanetworkopen.2020.25109. [5] Addeo, A., Banna, G.L., and Weiss, G.J. (2019). Tumor mutation burden-from hopes to doubts. JAMA Oncol. 5: 934−935. DOI: 10.1001/jamaoncol.2019.0626. [6] Valero, C., Lee, M., Hoen, D., et al. (2021). The association between tumor mutational burden and prognosis is dependent on treatment context. Nat. Genet. 53: 11−15. DOI: 10.1038/s41588-020-00752-4. [7] Pich, O., Muinos, F., Lolkema, M.P., et al. (2019). The mutational footprints of cancer therapies. Nat. Genet. 51: 1732−1740. DOI: 10.1038/s41588-019-0525-5. [8] Meira-Machado, L., Cadarso-Suarez, C., Gude, F., et al. (2013). SmoothHR: An R package for pointwise nonparametric estimation of hazard ratio curves of continuous predictors. Comput. Math. Methods Med. 2013: 745742. DOI: 10.1155/2013/745742. [9] National Cancer Institute. Surveillance, Epidemiology, and End Results Program. (2022). SEER*Explorer. https://seer.cancer.gov/explorer/. [10] Crisafulli, G., Sartore-Bianchi, A., Lazzari, L., et al. (2022). Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients. Cancer Discov. 12: 1656−1675. DOI: 10.1158/2159-8290.CD-21-1434. -
ABOUT THIS ARTICLE
Cite this article:
Zheng M. (2023). Self-limited cancer progression with increasing tumor mutations. The Innovation Medicine 1(3), 100039. https://doi.org/10.59717/j.xinn-med.2023.100039
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Export File
Citation
Zheng M. (2023). Self-limited cancer progression with increasing tumor mutations. The Innovation Medicine 1(3), 100039. https://doi.org/10.59717/j.xinn-med.2023.100039
Format
Content
DownLoad:
-
Figure 1.
Landscape of cancer progression across increasing tumor mutation burden (TMB) levels
